Site Editor

Leo I. Gordon, MD, FACP


Epcoritamab Accepted for Priority Review by FDA in Treatment of LBCL

By: JNCCN 360 Staff
Posted: Tuesday, November 29, 2022

On November 21, Genmab A/S announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the biologics license application for subcutaneous epcoritamab (DuoBody®-CD3xCD20) for the treatment of patients with relapse or refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy. The FDA has set a target action date of May 21, 2023. The investigational bispecific antibody is being co-developed by Genmab and AbbVie.

The application is based on safety and preliminary efficacy data from the LBCL cohort of the pivotal EPCORE NHL-1 open-label, multicenter phase II clinical trial evaluating epcoritamab in patients with relapsed, progressive, or refractory CD20-positive mature B-cell non-Hodgkin lymphoma. These results were presented in a late-breaking oral presentation as a part of the Presidential Symposium at the 2022 Annual Meeting of the European Hematology Association (EHA).

At EHA2022, the investigators reported the primary results for 157 patients with B-cell lymphomas. At a median follow-up of 10.7 months, the overall response rate was 63%, with 39% being complete responses. The median duration of response was 12 months; the median duration of response among patients achieving a complete response was not reached, with 89% still in complete response at 9 months. The most common treatment-emergent adverse events of any grade were cytokine-release syndrome (49.7%), pyrexia (23.6%), fatigue (22.9%), neutropenia (21.7%), and diarrhea (20.4%).

An ongoing phase III, open-label, randomized clinical trial is evaluating epcoritamab as a monotherapy in patients with relapsed or refractory diffuse LBCL ( identifier NCT04628494). In addition, a phase III open-label clinical trial is evaluating epcoritamab in combination in patients with relapsed or refractory follicular lymphoma (NCT05409066).

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.